• Who we are
    • About us
    • Our values
    • Environmental, social & governance
    • Therapeutic areas
  • What we do
    • Consulting (Acsel Health)
    • HEOR & market access
    • Scientific communications
    • Creative communications
    • Patient engagement
  • Insights
  • News & Events
  • Join us
    • Careers
    • Reasons to join
  • Contact us
  • Menu Menu

Publication Library / Publications

Work productivity in HER2 positive breast cancer: A comparison of patients across stages of early and metastatic disease

Objectives

While the clinical impact of HER2+ breast cancer (HER2+BC) is well described, data on the societal impact are lacking. This study compared work productivity in three HER2+ patient groups: early (E)BC during adjuvant treatment, EBC post-treatment, and metastatic (M)BC.

Methods

A cross-sectional, observational study of 299 consenting female patients recruited from 14 secondary care centres. Group1 (n=89): receiving targeted HER2 therapy±chemotherapy for EBC; Group2 (n=108): in follow-up post-targeted treatment for EBC; Group3 (n=102): MBC on treatment. Patients completed questionnaires including the Work Productivity and Activity Impairment (WPAI) measure and EQ-5D-5L; clinical staff collected patient and disease characteristics from medical records. Associations and inter-group differences were assessed using correlational analysis and univariate analysis of variance (ANOVA). [NCT03099200].

Results

Fewer Group3 patients were employed (n=28) compared to Group1 (n=45) and Group2 (n=55) (p<0.003), with more reporting an inability to work (Group3: n=27, Group1: n=7, Group2: n=5) (p<0.003). Of employed patients, Group2 reported lower mean (SD) levels of work absenteeism (9% [24%]) and overall work impairment (26% [31%]), compared to Group1 (38% [44%]; p<0.001 and 49% [40%]; p=0.015, respectively), and marginally lower mean (SD) levels of absenteeism than Group3 (31% [44%]; p=0.068). Across all patients (including unemployed), mean (SD) activity impairment in Group1 (34% [28%]) and Group2 (28% [26%]) was lower than in Group3 (48% [31%]; p<0.005). Across groups, higher work and activity impairments were associated with lower EQ-5D-5L health utility: r=-.3950; p<0.001, and r=-0.6670; p<0.001, respectively.

Conclusions

The relatively low levels of absenteeism and work impairment reported by employed patients suggest that those who were able to work remained productive. However, a higher proportion of MBC patients were unable to work, and reported significantly higher levels of overall activity impairment compared to those with EBC. Impairment was related to health utility, reflecting the overall impact of advanced disease.

Authors M Verrill, P Schmid, J Retzler, A B Smith, C J Bottomley, S Dando, I Tran, I Leslie, A M Wardley
Journal Value in Health
Therapeutic Area Oncology
Center of Excellence Patient-Centered outcomes, Real-world Evidence & Data Analytics
Year 2017
Read full article

Services

  • Consulting
  • HEOR & market access
  • Scientific communications
  • Creative communications
  • Patient engagement

Company

  • About Us
  • Our values
  • Environmental, social & governance
  • Our commitment to rare disease
  • Careers
  • Reasons to join
  • News & insights
  • Events
  • Locations & contact

Legal and Governance

  • Terms of use
  • Privacy notice
  • Cookie policy
  • IT security measures
  • Modern slavery statement
  • Disclosure UK – ABPI
  • Looking for OpenHealth Company?
  • Legal statements & documents
  • Global ethical business conduct code
  • Suppliers
footer-logo-mark
  • Twitter
  • Linkedin
  • Instagram
  • Facebook

© Copyright OPEN Health 2025. All rights reserved. OPEN Health is a registered trademark.

backtotop-arrow
Scroll to top